Hikma Names Sandoz’ Genestin As New Generics BD Chief
As Sandoz Recruits From Teva To Replace Departing Head Of BD&L
Hikma has named Patrick Genestin as its new head of business development for generics, bringing to the role 25 years of experience that includes most recently a 15-year stint at Sandoz. In turn, Sandoz has looked to Teva for a successor.
You may also be interested in...
Fresh from resuming launch of its generic version of Advair in the US, Hikma has also been boosted by an FDA approval for its 505(b)(2) naloxone 8mg nasal spray. Both developments are expected to drive the firm’s generics business to the top end of its guidance for 2021, management revealed.
Four key “moving pieces,” including the next developments for rivals to Advair and Vascepa, will influence the success of Hikma’s US generics business, CEO Siggi Olafsson tells Generics Bulletin in the first part of an exclusive interview.
The FDA’s acceptance of Amneal’s filing for bevacizumab brings the company a step closer to its goal of launching a US biosimilar every year to 2023.